Supplementary Table 1. Values of each of 5 components of PHES for control group and patients with and without MHE at baseline and at follow-up

DST	Control group	Pre-treatment		Post-SVR	
		MHE– (*n* = 87)	MHE+ (*n* = 17)	MHE– (*n* = 81)	MHE+ (*n* = 23)
NCT-A	30 ±13	29 ±10	15 ±5	33 ±10	17 ±9
NCT-B	68 ±27	65 ±23	121 ±33	64 ±25	120 ±39
SDT	139 ±85	131 ±64	374 ±160	139 ±82	312 ±102
SDT	47 ±10	58 ±33	87 ±32	52 ±10	84 ±20
LDT	92 ±30	104 ±28	174 ±53	101 ±26	160 ±45

DST – digit symbol test, number connection test-A, number connection test-B, serial dotting test, and line drawing test. For DST, values are expressed as number of correct minus wrong answers in 90 seconds. For all other tests, values are expressed as time in seconds+ errors; p-value < 0.001 for comparisons between patients with and without MHE at same time point for any of the five tests.

Supplementary Table 2. Changes of liver function and portal hypertension related parameters after SVR in patients with new-onset MHE (*n* = 10)

Parameter	Baseline	SVR	*p*-value
Bilirubin (mg/dl)	0.8 ±0.5	0.7 ±0.5	0.024
Albumin (g/l)	33 ±4	37 ±3	0.019
INR	1.18 ±0.15	1.15 ±0.13	0.49
AST (U/l)	74 ±27	27 ±7	< 0.01
ALT (U/l)	78 ±44	28 ±11	< 0.01
Platelet count (× 10^9/l)	142 ±63	146 ±70	0.74
Liver stiffness measurement (kPa)	22 ±26	18 ±20	0.18
Child-Pugh	6.3 ±0.8	5.9 ±0.9	< 0.01
MELD	9.1 ±2.2	8.7±2.1	0.08

Number of patients with variables available for comparisons: 10 (platelet count, AST, ALT), 9 (bilirubin, albumin), 7 (INR, MELD, Child-Pugh) and 6 (liver stiffness).